Henry Schein's Double Edged Momentum Henry Schein's latest earnings report reveals a mix of encouraging signs and cautionary warnings for investors.
The company's dental business has demonstrated remarkable resilience, with steady growth in April and May, while its medical sales have been hurt by a weaker than expected respiratory illness season.
The company is aiming to achieve $125 million in net run rate value creation by the end of 2026, but this ambitious target relies heavily on significant cost cutting measures.